StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research note published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a report on Thursday, November 14th.

Trevena Price Performance

TRVN opened at $1.86 on Wednesday. The business has a fifty day moving average price of $1.70 and a 200 day moving average price of $3.17. Trevena has a 12 month low of $1.13 and a 12 month high of $17.51. The stock has a market capitalization of $1.60 million, a price-to-earnings ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The firm had revenue of $0.28 million during the quarter. On average, research analysts anticipate that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.